España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Braxia Scientific
BRAXF
OTCPK
Watchlist
Get Report
Perks
Buy
Compare Brokers
$0.003700
-0.0003
-8.64%
At Close: -
15 minutes delayed
Get Report
Watch
Braxia Scientific (BRAXF) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Braxia Scientific (OTC:BRAXF) Stock
Braxia Scientific Stock (OTC: BRAXF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Saturday, March 02, 2024
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
Lara Goldstein
Thursday, February 29, 2024
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Lara Goldstein
Monday, December 11, 2023
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
Lara Goldstein
Monday, December 04, 2023
Braxia Scientific's Q2 2024: Cash Burn Over But Income Low, What's Next For Psychedelics Company?
Lara Goldstein
Tuesday, September 05, 2023
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Lara Goldstein
Thursday, August 31, 2023
Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss
Lara Goldstein
Tuesday, June 13, 2023
Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
Lara Goldstein
Friday, June 09, 2023
BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
Lara Goldstein
Monday, March 20, 2023
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Lara Goldstein
Thursday, March 16, 2023
Major Ketamine Clinics Chain Decides Not To Pursue Acquisition Deal
Lara Goldstein
Tuesday, March 07, 2023
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Lara Goldstein
Thursday, March 02, 2023
Braxia Scientific's Q3 2023 Finances, Update On Upcoming Acquisition With Irwin Naturals
Lara Goldstein
Tuesday, February 21, 2023
Irwin Naturals Acquires Ketamine Clinic In Kentucky Adding $3M In Projected EBITDA
Vuk Zdinjak
Friday, January 27, 2023
Irwin Naturals Signs LOI To Acquire Braxia Scientific Expanding Its Network Of Mental Health Clinics
Vuk Zdinjak
Tuesday, January 10, 2023
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Lara Goldstein
Tuesday, December 06, 2022
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Lara Goldstein
Friday, December 02, 2022
Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY
Joana Scopel
Friday, October 07, 2022
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Lara Goldstein
Wednesday, October 05, 2022
Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
Lara Goldstein
Tuesday, September 13, 2022
Great Psychedelics And Business Events Are Coming In Q4: Check Them Out Here
Lara Goldstein
Tuesday, August 30, 2022
4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
Lara Goldstein
Wednesday, August 03, 2022
Telehealth Market News: Braxia Scientific Enters Industry By Acquiring Ketamine Treatment Platform In Florida
Lara Goldstein
Monday, August 01, 2022
Braxia Scientific Fiscal 2022 Revenue Grows 47.5% YoY, What About Net Loss?
Vuk Zdinjak
Thursday, June 16, 2022
Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
Lara Goldstein
Wednesday, June 15, 2022
Braxia Opens New Clinic in Ontario, Facilitating Further Access To Ketamine And Psilocybin Treatments
Lara Goldstein
Thursday, June 02, 2022
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
Natan Ponieman
Monday, October 18, 2021
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman
Wednesday, October 13, 2021
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman
Monday, October 04, 2021
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
Natan Ponieman
Thursday, September 30, 2021
New Study Suggests Ketamine Could Work Better Without Additional Antidepressants
Natan Ponieman
Monday, August 30, 2021
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Natan Ponieman
Friday, August 27, 2021
Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression
Natan Ponieman
Monday, August 02, 2021
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Natan Ponieman
Wednesday, July 28, 2021
Braxia Scientific Leadership Receives Funding From Canadian Government To Study Ketamine Therapy
Natan Ponieman
Monday, July 26, 2021
Psyched: Cybin And Field Trip Head To Wall Street, AOC Pushes For Federal Psychedelics Research, Off-Label Ketamine Covered By Insurance In Canada
Natan Ponieman
Thursday, July 22, 2021
Canadian Insurance Provider To Cover Off-Label Use Of Ketamine For Treating Depression
Natan Ponieman
Friday, July 02, 2021
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Natan Ponieman
Monday, June 21, 2021
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Natan Ponieman
